The Quaternary Group investment portfolio

1NHALER Ltd develops a propellant‑free, cardboard‑based single‑dose dry‑powder inhaler that folds from a flat credit‑card shape into a three‑dimensional device, using patented membrane dispersion technology to deliver a range of inhalable medicines. The company partners with pharmaceutical organisations and public‑health bodies to provide low‑cost, portable inhalation therapy for conditions such as asthma, epilepsy, allergies and Parkinson’s disease.

Bead BioPharma develops a proprietary chemistry platform that enhances the durability and safety of antibody‑drug conjugates (ADCs) for cancer therapy, targeting the oncology drug‑development market.